Talaris Therapeutics, Inc.

Symbol: TALS




Market price today

  • -1.6663

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 116.44M

    MRK Cap

  • 0.56%

    DIV Yield

Talaris Therapeutics, Inc. (TALS) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Mary Kay Fenton
Full-time employees:84
Address:570 South Preston Street

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

General Outlook

In simple terms, Talaris Therapeutics, Inc. has 42.811 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.433% return, is a testament to Talaris Therapeutics, Inc.'s adeptness in optimizing resource deployment. Talaris Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.402%. Furthermore, the proficiency of Talaris Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.538% return on capital employed.

Stock Prices

Talaris Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.96, while its low point bottomed out at $2.82. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Talaris Therapeutics, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Talaris Therapeutics, Inc. (TALS) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -1.666 in 2023.

What is the ticker symbol of Talaris Therapeutics, Inc. stock?

The ticker symbol of Talaris Therapeutics, Inc. stock is TALS.

What is company IPO date?

IPO date of Talaris Therapeutics, Inc. is 2021-05-07.

What is company current share price?

Current share price is 2.720 USD.

What is stock market cap today?

The market cap of stock today is 116444832.000.

What is PEG ratio in 2023?

The current 0.000 is 0.000 in 2023.

What is the number of employees in 2023?

In 2023 the company has 84.